Briefs

May 17, 2006. Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, announced that the National Cancer Institute has awarded Insightful two Phase II contracts worth $1,394,027. The contracts call for Insightful to develop over the next two years, analytic methods to identify protein biomarkers and to create S+Proteome�, a flexible and easy to use software environment for processing and analyzing protein mass spectral data

The National Cancer Institute awarded Insightful these contracts to develop technology solutions that will aid researchers in identifying biomarkers in their effort to detect cancer in its earliest stages.

Also, this week SunGard announced that SunGard�s FAME data management solution for managing high-volume time series data (http://www.sungard.com/fame) will integrate with Insightful�s S-PLUS� software platform for statistical data analysis and predictive analytics (http://www.insightful.com/ ). An integration module linking S-PLUS and FAME, called FAME S+Connector�, will help financial institutions� research and investment analysts improve the speed and ease of optimizing portfolios, assessing risk exposure, conducting alpha tests, and identifying market opportunities.

In today's financial institutions, quantitative methods are required to maintain a sustainable competitive advantage. With FAME S+Connector quantitative analysts can be more productive and respond more quickly to demands from their line of business customers. SunGard will be the primary seller and distributor of FAME S+Connector

For more information, visit www.insightful.com.